Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) EBT: 2021-2025

Historic EBT for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Sep 2025 value amounting to $7.5 million.

  • Arcutis Biotherapeutics' EBT rose 118.03% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.3 million, marking a year-over-year increase of 77.82%. This contributed to the annual value of -$139.4 million for FY2024, which is 46.19% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its EBT stood at $7.5 million for Q3 2025, which was up 148.19% from -$15.5 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' EBT ranged from a high of $7.5 million in Q3 2025 and a low of -$107.7 million during Q3 2022.
  • Its 3-year average for EBT is -$39.2 million, with a median of -$41.5 million in 2024.
  • Per our database at Business Quant, Arcutis Biotherapeutics' EBT plummeted by 88.70% in 2022 and then skyrocketed by 118.03% in 2025.
  • Quarterly analysis of 5 years shows Arcutis Biotherapeutics' EBT stood at -$71.3 million in 2021, then decreased by 1.03% to -$72.0 million in 2022, then climbed by 8.00% to -$66.3 million in 2023, then spiked by 84.21% to -$10.5 million in 2024, then skyrocketed by 118.03% to $7.5 million in 2025.
  • Its EBT stands at $7.5 million for Q3 2025, versus -$15.5 million for Q2 2025 and -$24.8 million for Q1 2025.